Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
December 4th, 2020
At Intellia, we are building a full-spectrum, product-driven biotechnology company focused on our mission of developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.